THE NEW BUSINESS MODEL FOR EXPANDED HEMATOLOGY PARAMETERS – IMMATURE GRANULOCYTE (IG)
THE NEW BUSINESS MODEL FOR EXPANDED HEMATOLOGY PARAMETERS – IMMATURE GRANULOCYTE (IG)

These are transformative times in the healthcare industry and especially for the clinical laboratory. Significant reimbursement
cuts and payment reform linked to quality measures are driving a new approach to laboratory testing. Laboratorians faced with a
changing business model and growing staff shortages are increasingly being asked to justify the value the laboratory provides.

LEARN MORE
IMMATURE GRANULOCYTE (IG) POPULATIONS MAY IMPROVE THE ASSESSMENT OF INFECTION AND SEPSIS
IMMATURE GRANULOCYTE (IG) POPULATIONS MAY IMPROVE THE ASSESSMENT OF INFECTION AND SEPSIS

The diagnosis of sepsis is complex due to the wide variety of nonspecific symptoms and the absence of a definitive diagnostic marker. Total and differential blood leukocyte counts are some of the tools used in the clinical investigation of sepsis. Laboratories can now report on the population of immature granulocytes with a high degree of accuracy through the Sysmex IG parameter, recognized as an infection / inflammation biomarker and an important indicator of sepsis

LEARN MORE